Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization
Spurr, Ian B., Birts, Charles N., Cuda, Francesco, Benkovic, Stephen J., Blaydes, Jeremy P. and Tavassoli, Ali (2012) Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization. ChemBioChem, 13, (11), 1628-1634. (doi:10.1002/cbic.201200279). (PMID:22764122).
Full text not available from this repository.
Aminoimidazole carboxamide ribonucleotide transformylase/ inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis. Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å(2) , is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins. Here, we report the development of a small-molecule inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC. The compound is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a K(i) of 17 μM), identified by high-throughput screening. The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analogue of which inhibits AICAR transformylase with a K(i) value of 84 μM. A library of nonnatural analogues of this dipeptide was designed, synthesized, and assayed. The most potent compound inhibits AICAR transformylase with a K(i) value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide. The potential for this AICAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line. Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent reduction in cell numbers and cell division rates was observed in cells treated with our ATIC dimerization inhibitor.
|Keywords:||AICAR transformylase, ATIC, cancer, peptides, protein–protein interaction inhibitors|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Medicine > Cancer Sciences
Faculty of Natural and Environmental Sciences > Chemistry
Faculty of Natural and Environmental Sciences > Chemistry > Chemical Biology Group
|Date Deposited:||23 Jul 2012 10:59|
|Last Modified:||27 Feb 2014 19:32|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)